ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned

Simonetta Viviani, Pier Luigi Zinzani, Alessandro Rambaldi, +17

New England Journal of Medicine

Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma

Marco Ladetto, G Pagliano, Simone Ferrero, +17

Journal of Clinical Oncology

Cell TherapyAutografted MyelomaImmunologyPathologyImmunotherapy +17

Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP

Patrizia Pregno, Annalisa Chiappella, Marilena Bellò, +16

Blood

Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma.

Antonio Palumbo, Luisa Giaccone, Alessandra Bertola, +6

PubMed

Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma

Antonio Palumbo, Maria Teresa Ambrosini, Giulia Benevolo, +11

Blood

Interim Positron Emission Tomography Response–Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study

Pier Luigi Zinzani, Alessandro Broccoli, Daniela Gioia, +25

Journal of Clinical Oncology

Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma

Antonio Palumbo, Alessandra Bertola, Patrizia Falco, +8

The Hematology Journal

Hematological MalignancyMedicineHematologyPharmacologyMultiple Myeloma +5

Positron emission tomography in the staging of patients with Hodgkin’s lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi

Luigi Rigacci, Umberto Vitolo, Luca Nassi, +14

Annals of Hematology

Positron Emission TomographyProspective Multicentric StudyLymphoid NeoplasiaOncologic ImagingMedical Imaging +7

Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party

Gabriele Gugliotta, Fausto Castagnetti, Francesca Palandri, +22

Blood

Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission

Monica Bocchia, Anna Sicuranza, Elisabetta Abruzzese, +31

Frontiers in Oncology